Daniel Gilbert
Verified
As seen in:
CBS News,
MSN,
MSN Canada,
MSN Ireland,
UOL,
Yahoo Life,
Nature,
The Wall Street Journal,
The Washington Post,
Yahoo Canada,
Yahoo News
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Gilbert
Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? Original
The Food and Drug Administration received reports in recent months that two people died after taking bootleg versions of an experimental weight-loss drug, according to documents reviewed by CBS News. The reports link the deaths to products claiming to be retatrutide, a drug being developed by Eli Lilly that hasn't been approved by the FDA.
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know. Original
The Food and Drug Administration has warned a major compounding pharmacy that it violated federal law by making copies of blockbuster weight-loss drugs in "inordinate amounts." The letter to Empower Pharmacy marks the first time the FDA has waded into a fierce debate about when a pharmacy's legitimate work of customizing a medication crosses the line into mass-copying of patented FDA-approved drugs. The FDA's warning, dated Sept.
A trusted seal made these websites look legit. The weight-loss drug they sold wasn't.
The ads for an illicit weight-loss drug are all over social media. A selection of ads for retatrutide from Facebook. A selection of ads for retatrutide from Facebook. "Imagine food finally shutting the hell up in your head. That's why people are watching reta," a narrator says in one video ad, referring to the experimental drug retatrutide, as a heavyset woman stares at a plate of food.
Eli Lilly takes aim at illicit market for its experimental weight-loss drug Original
Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit market. That market has boomed even though retatrutide is still being studied in clinical trials and hasn't been approved by the Food and Drug Administration as safe and effective.
Judge sentences peptide vendor to nearly 6 years in prison for "an incredible trail of harm"
Conservative View 1 hour ago Trump Education Department probes school after teacher allegedly required same-sex students to kiss Fox News - Rachel del Guidice • 1h The Trump administration has opened a federal investigation into Denver Public Schools after allegations that a high school teacher required students of the same sex to kiss as part of a classroom assignment, the Department of Education announced Tuesday.
In the unbridled online marketplace for peptides, one vendor is sentenced to nearly 6 years in prison Original
SOUTH BEND, Ind. – A federal judge on Thursday sentenced the owner of a peptide company to nearly six years in prison after finding he built a massive business by deceiving customers and selling products that were adulterated with steroids. Matthew Kawa, who ran Paradigm Peptides, pleaded guilty last year to selling unapproved drugs and illegally importing them from abroad.
What a Brooklyn bodega reveals about the craze for an experimental weight-loss drug Original
Behind the counter of a bodega in Brooklyn, a cashier casually rang up a tiny vial of a peptide the store advertised as retatrutide — an experimental weight-loss drug whose sale is generally prohibited by federal law. "PEPTIDES SOLD HERE" reads a large sign displayed on the storefront of Mr. Green, a small shop on a busy stretch of Bedford Avenue sandwiched between a poke restaurant and a funeral home.
How an experimental weight-loss drug is being openly promoted by physicians
Updated Mon, June 8, 2026 at 10:31 AM UTC How an experimental weight-loss drug is being openly promoted by physicians Retatrutide isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and Drug Administration hasn't reviewed whether it is safe and effective, which is the legal path for prescription drugs to come to market.
How an experimental weight-loss drug is being openly promoted by physicians
Retatrutide isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and Drug Administration hasn't reviewed whether it is safe and effective, which is the legal path for prescription drugs to come to market. And yet retatrutide is for sale all over the internet, a phenomenon with no modern precedent.
Longevity guru Peter Attia exits CBS News after Epstein emails surface
Scott Nover, Daniel Gilbert Peter Attia, a physician and prominent longevity influencer, is stepping down from his role as a CBS News contributor after the Justice Department released hundreds of previously undisclosed emails between him and convicted sex offender Jeffrey Epstein, according to two people familiar with the decision, who spoke on the condition of anonymity to share private employment details.
Super Bowl spot will promote a cancer test that can produce false results
A telehealth company that generated buzz last year with a defiant Super Bowl ad hawking weight-loss drugs is back for this year’s championship with a socially charged pitch around longevity. “Rich people live longer,” intones the artist Common, as the spot for Hims & Hers advises that you, too, can get access to the same “custom-formulated peptides,” hormone therapy and other wellness products as the wealthy.
Super Bowl spot will promote a cancer test that can produce false results
Super Bowl spot will promote a cancer test that can produce false results (washingtonpost.com) Super Bowl spot will promote a cancer test that can produce false results By Daniel Gilbert 2026020610041200 A telehealth company that generated buzz last year with a defiant Super Bowl ad hawking weight-loss drugs is back for this year's championship with a socially charged pitch around longevity.
The next frontier in weight-loss drugs: one-time gene therapy
The next frontier in weight-loss drugs: one-time gene therapy (washingtonpost.com) The next frontier in weight-loss drugs: one-time gene therapy By Daniel Gilbert 2026012410010600 When Harith Rajagopalan considers the millions of patients who have taken a GLP-1 drug to treat diabetes or obesity, he sees a revolution that is failing to realize its promise. "We are literally lighting tens of billions of dollars on fire," he said.
Can your health records be sold for profit? A lawsuit says it’s happening.
Can your health records be sold for profit? A lawsuit says it’s happening. (washingtonpost.com) Can your health records be sold for profit? A lawsuit says it’s happening. By Daniel Gilbert 2026012210013200 On the digital superhighway that allows sensitive patient health records to be shared by hospitals and doctors, something seemed off to engineers at Epic Systems: Among the providers with access to the network were names that sounded like law firms.
This innovation saved lives in the pandemic. Now it’s showing strength against cancer.
This innovation saved lives in the pandemic. Now it’s showing strength against cancer. (washingtonpost.com) This innovation saved lives in the pandemic. Now it’s showing strength against cancer. By Daniel Gilbert 2026012011560300 An experimental drug custom-made to target the genetic mutations of individual tumors showed promise in treating aggressive skin cancer, according to new results from a clinical trial announced Tuesday.
MRNA helped end the pandemic. Now it shows promise against skin cancer.
The 3 Most Reliable Dividend Stocks to Buy for Years to Come In an uncertain and volatile market, dividend stocks are often the first choice for investors looking for reliable income. Companies that have a …
“Ya no será sinónimo de muerte”: un cóctel de drogas da vida y esperanza a los pacientes con una agresiva forma de cáncer
En el mieloma múltiple, las células cancerosas se multiplican en la médula ósea y diseminan tumores WASHINGTON.– El oncólogo Luciano Costa tuvo que esperar tres años para saber cómo les había ido a los pacientes de una agresiva forma de cáncer de médula que habían recibido un tratamiento experimental de inmunoterapia. Pero al revisar los resultados, al médico se le puso la piel de gallina.
This cancer is stubborn, but new drug regimen shows promise Original
This cancer is stubborn, but new drug regimen shows promise (washingtonpost.com) This cancer is stubborn, but new drug regimen shows promise By Daniel Gilbert 2026011510011900 Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. "Holy shit," the oncologist thought.
People with depression can treat themselves at home with new device
An in-home headset that allows people with depression to send mild electrical current to their brains has been cleared by the Food and Drug Administration, in what medical experts consider a milestone for expanding mental health treatment beyond drugs. The prescription device, made by Flow Neuroscience, is designed to counteract moderate to severe depression in adults by delivering electric stimulation to an area of the brain that controls mood and stress.
Quest for a drug that lowers an artery-clogging particle nears finish line
A fatty particle can clog arteries just as surely as cholesterol but often goes undetected, striking seemingly healthy people unaware of the danger. Though tests are widely available, they aren’t routinely ordered — in part because there are no approved treatments for the genetic disorder. Now, cardiologists waging a campaign against lipoprotein(a) say they are reaching a turning point.
Former GLP-1 users regain lost weight after about 18 months, study says
People who stop taking GLP-1 drugs such as Ozempic and Wegovy for weight loss are projected to regain their shed pounds within about 1½ years, a review of existing research has found. The paper also found that former users of a wider list of weight-loss drugs regain weight four times more quickly than those who had used behavioral techniques like dieting or exercise.
First GLP-1 weight-loss pill is now available, with pledge of abundant supply
Novo Nordisk launched the first GLP-1 weight-loss pill Monday with a pledge that manufacturing investments will enable the drugmaker to avoid the type of shortages that plagued the rollout of its injectable version. The company said doctors can now prescribe the new oral version of Wegovy and patients can pick it up at more than 70,000 pharmacies and via mail-order services throughout the country.
First GLP-1 weight-loss pill is now available, with pledge of abundant supply
First GLP-1 weight-loss pill is now available, with pledge of abundant supply (washingtonpost.com) First GLP-1 weight-loss pill is now available, with pledge of abundant supply By Daniel Gilbert 2026010513001000 Novo Nordisk launched the first GLP-1 weight-loss pill Monday with a pledge that manufacturing investments will enable the drugmaker to avoid the type of shortages that plagued the rollout of its injectable version.
Quest for a drug that lowers an artery-clogging particle nears finish line
HEALTH Daniel Gilbert The Washington Post Jan. 2, 2026, 9:31 a.m. ET View Comments A fatty particle can clog arteries just as surely as cholesterol but often goes undetected, striking seemingly healthy people unaware of the danger. Though tests are widely available, they aren’t routinely ordered - in part because there are no approved treatments for the genetic disorder. Now, cardiologists waging a campaign against lipoprotein(a) say they are reaching a turning point.
A hidden risk to your heart has no treatment, but that could soon change
A fatty particle can clog arteries just as surely as cholesterol but often goes undetected, striking seemingly healthy people unaware of the danger. Though tests are widely available, they arent routinely ordered in part because there are no approved treatments for the genetic disorder. Now, cardiologists waging a campaign against lipoprotein(a) say they are reaching a turning point.
People with depression now can treat themselves using a headset device
An in-home headset that allows people with depression to send a mild electrical current to their brains has been cleared by the Food and Drug Administration, in what medical experts consider a milestone for expanding mental health treatment beyond drugs. The prescription device, made by Flow Neuroscience, is designed to counteract moderate to severe depression in adults by delivering electric stimulation to an area of the brain that controls mood and stress.
The FDA just approved the first GLP-1 weight-loss pill. Here’s what to know.
The Food and Drug Administration has approved the first GLP-1 pill for weight loss, its manufacturer Novo Nordisk announced Monday, a milestone in the growth of the revolutionary drug. The drug, a once-a-day Wegovy tablet, also is approved for reducing cardiovascular risk. The pill is expected to increase accessibility for people who don’t like injections. “The pill is here,” Mike Doustdar, the Denmark-based drugmaker’s CEO, said in a statement. Wegovy will soon face competition.
People with depression can treat themselves at home with new device
Getting your Trinity Audio player ready... By Daniel Gilbert The Washington Post An in-home headset that allows people with depression to send mild electrical current to their brains has been cleared by the Food and Drug Administration, in what medical experts consider a milestone for expanding mental health treatment beyond drugs.
The FDA just approved the first GLP-1 weight-loss pill. Here’s what to know.
The FDA just approved the first GLP-1 weight-loss pill. Here’s what to know. (washingtonpost.com) The FDA just approved the first GLP-1 weight-loss pill. Here’s what to know. By Daniel Gilbert 2025122314001900 The Food and Drug Administration has approved the first GLP-1 pill for weight loss, its manufacturer Novo Nordisk announced Monday, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day Wegovy tablet, also is approved for reducing cardiovascular risk.
People with depression can be treated at home with device
An in-home headset that allows people with depression to send mild electrical current to their brains has been cleared by the Food and Drug Administration, in what medical experts consider a milestone for expanding mental health treatment beyond drugs. The prescription device, made by Flow Neuroscience, is designed to counteract moderate to severe depression in adults by delivering electric stimulation to an area of the brain that controls mood and stress.
People with depression can treat themselves at home with new device
An in-home headset that allows people with depression to send mild electrical current to their brains has been cleared by the Food and Drug Administration, in what medical experts consider a milestone for expanding mental health treatment beyond drugs. The prescription device, made by Flow Neuroscience, is designed to counteract moderate to severe depression in adults by delivering electric stimulation to an area of the brain that controls mood and stress.
People with depression can treat themselves at home with new device
An in-home headset that allows people with depression to send mild electrical current to their brains has been cleared by the Food and Drug Administration, in what medical experts consider a milestone for expanding mental health treatment beyond drugs. The prescription device, made by Flow Neuroscience, is designed to counteract moderate to severe depression in adults by delivering electric stimulation to an area of the brain that controls mood and stress.
FDA to investigate whether adult deaths linked to coronavirus vaccine
"FDA is doing a thorough investigation, across multiple age groups, of deaths potentially related to coronavirus vaccines," said a spokesman for the Department of Health and Human Services Author of the article: Washington Post Daniel Gilbert, Rachel Roubein Published Dec 10, 2025 • 3 minute read You can save this article by registering for free here. Or sign-in if you have an account. The FDA to investigate whether adult deaths linked to coronavirus vaccine.
FDA to investigate whether adult deaths linked to coronavirus vaccine
The Food and Drug Administration is investigating whether coronavirus vaccines are linked to deaths of adults, part of an investigation that has alleged children died as a result of the shots, federal health officials said Tuesday. “FDA is doing a thorough investigation, across multiple age groups, of deaths potentially related to coronavirus vaccines,” said Andrew Nixon, a spokesman for the Department of Health and Human Services.
FDA to probe whether adult deaths linked to coronavirus vaccine
The Food and Drug Administration is investigating whether coronavirus vaccines are linked to deaths of adults, part of a probe that has alleged children died as a result of the shots, federal health officials said Tuesday. FDA is doing a thorough investigation, across multiple age groups, of deaths potentially related to coronavirus vaccines, said Andrew Nixon, a spokesman for the Department of Health and Human Services.
Ozempic 2.0 is on the way, and it could be even more transformative
Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of millions of patients who’ve lost unprecedented amounts of weight. On grocery store shelves with new offerings explicitly catering to those taking the drugs. Even in the calculations of insurance companies studying the drugs’ effects on mortality.
Ozempic 2.0 is on the way, and it could be even more transformative
Ozempic 2.0 is on the way, and it could be even more transformative (washingtonpost.com) Ozempic 2.0 is on the way, and it could be even more transformative By Daniel Gilbert 2025112710005000 Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of millions of patients who've lost unprecedented amounts of weight. On grocery store shelves with new offerings explicitly catering to those taking the drugs.
A pill is raising hope for one of the deadliest cancers. How fast should patients get it?
By Daniel Gilbert The Washington Post At 69 years old, Debby Orcutt was diagnosed last year with pancreatic cancer, a condition so dire that her doctor refused to tell her how long she had to live. With few good options, she enrolled in a clinical trial for an experimental drug. “I just looked at it like, what have I got to lose?” she said. “I’m gonna die.” A scan last week showed her tumor had shrunk 64 percent since starting the drug in January, according to her husband.
Pill raises hope for cancer treatment: How fast patients should get it.
At 69 years old, Debby Orcutt was diagnosed last year with pancreatic cancer, a condition so dire that her doctor refused to tell her how long she had to live. With few good options, she enrolled in a clinical trial for an experimental drug. “I just looked at it like, what have I got to lose?” she said. “I’m gonna die.” A scan last week showed her tumor had shrunk 64 percent since starting the drug in January, according to her husband.
What you need to know about Medicare coverage for weight-loss drugs
President Donald Trump’s deals to lower the price of weight-loss drugs announced on Thursday could break through a stalemate that has left the medications out of reach for millions of patients who could benefit from them. Novo Nordisk and Eli Lilly, the dominant manufacturers of GLP-1 drugs on the market, have agreed to offer lower prices in exchange for getting Medicare coverage for the drugs for some beneficiaries, which will increase the number of people buying them.
What you need to know about Medicare coverage for weight-loss drugs
What you need to know about Medicare coverage for weight-loss drugs (washingtonpost.com) What you need to know about Medicare coverage for weight-loss drugs By Daniel Gilbert 2025110715511300 President Donald Trump's deals to lower the price of weight-loss drugs announced on Thursday could break through a stalemate that has left the medications out of reach for millions of patients who could benefit from them.
Una píldora experimental genera esperanza contra uno de los cánceres más mortales
La FDA busca agilizar la llegada de tratamientos innovadores contra el cáncer de páncreas (Imagen Ilustrativa Infobae) A los 69 años, Debby Orcutt fue diagnosticada el año pasado con cáncer de páncreas, una enfermedad tan grave que su médico se negó a decirle cuánto tiempo le quedaba de vida. Ante la escasez de opciones, se inscribió en un ensayo clínico para un fármaco experimental. “Lo vi como diciendo: ¿qué tengo que perder?”, dijo. “Voy a morir”.
Trump, long fixated on ‘fat drug,’ to announce deal to lower its price
President Donald Trump has long pushed to cut the price of GLP-1 medications, often expressing frustration about the high cost of what he calls the “fat drug” in the United States. On Thursday, the president got his way, announcing concessions from Eli Lilly and Novo Nordisk that will lower the price of their weight-loss drugs for some patients covered by Medicare and Medicaid.
Trump, long fixated on ‘fat drug,’ announces deal to lower its price
Trump, long fixated on ‘fat drug,’ announces deal to lower its price (washingtonpost.com) Trump, long fixated on ‘fat drug,’ announces deal to lower its price By Dan Diamond; Daniel Gilbert; Paige Winfield Cunningham 2025110613441400 President Donald Trump has long pushed to cut the price of GLP-1 medications, frequently invoking his frustration about the high cost of what he has dubbed the "fat drug" in the United States.
A pill is raising hope for one of the deadliest cancers. The question is how fast patients should get it.
A pill is raising hope for one of the deadliest cancers. The question is how fast patients should get it. 1 of 2 At 69 years old, Debby Orcutt was diagnosed last year with pancreatic cancer, a condition so dire that her doctor refused to tell her how long she had to live. With few good options, she enrolled in a clinical trial for an experimental drug. “I just looked at it like, what have I got to lose?” she said.
A pill is raising hope for one of the deadliest cancers. The question is how fast patients should get it.
At 69 years old, Debby Orcutt was diagnosed last year with pancreatic cancer, a condition so dire that her doctor refused to tell her how long she had to live. With few good options, she enrolled in a clinical trial for an experimental drug. “I just looked at it like, what have I got to lose?” she said. “I’m gonna die.”
A pill is raising hope for one of the deadliest cancers. The question is how fast patients should get it.
At 69 years old, Debby Orcutt was diagnosed last year with pancreatic cancer, a condition so dire that her doctor refused to tell her how long she had to live. With few good options, she enrolled in a clinical trial for an experimental drug. I just looked at it like, what have I got to lose? she said. Im gonna die. A scan last week showed her tumor had shrunk 64 percent since starting the drug in January, according to her husband.
Texas sues Tylenol, taking cues from Trump and RFK Jr. Original
Texas sues Tylenol, taking cues from Trump and RFK Jr. (washingtonpost.com) Texas sues Tylenol, taking cues from Trump and RFK Jr. By Daniel Gilbert 2025102813174000 Texas Attorney General Ken Paxton filed a lawsuit Tuesday against Tylenol maker Kenvue and its former parent company, Johnson & Johnson, alleging the companies deceptively sold the painkiller despite knowing it could cause autism.
As new treatments for microplastics emerge, here’s the evidence on how well they work
As new treatments for microplastics emerge, here’s the evidence on how well they work (washingtonpost.com) As new treatments for microplastics emerge, here’s the evidence on how well they work By Shannon Osaka; Daniel Gilbert 2025101809000000 As Mike Petegorsky prepared to welcome his baby daughter, he worked to minimize his family's exposure to microplastics and other environmental toxins. The telehealth executive got rid of plastic Tupperware and utensils.
Show More
loading
Actions
Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack